Trends in U.S. Drug Use Among Hospitalized Parkinson’s Patients Experiencing Delirium
Objective: To examine drug use trends among hospitalized Parkinson’s disease (PD) patients in the U.S. and to assess the association between PD medications and delirium.…Predicting the Cognitive-Psychiatric Phenotype of Parkinson’s Disease
Objective: Predict PD patient’s clinical scores from brain activity. Inform on which assessments capture true changes in cortical dynamics caused by PD and explain those…Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies
Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.
Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…Diagnostic Challenges in Functional Neurological Disorder: Convergent Psychogenic Non-Epileptic Seizures and Psychosis
Objective: To dissect the diagnostic challenges in distinguishing Functional Neurological Disorder (FND) coexisting with psychosis, highlighting the imperative for comprehensive and nuanced neuro-psychiatric assessment. Background:…Conceptualization of the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS) prototype.
Objective: To outline the process of conceptualizing the prototype for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Approximately…Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study
Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period
Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report
Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »